高盛唱多寒武纪，目标价再度拔高！

Group 1 - The core viewpoint of the article highlights the discrepancy between market excitement and underlying financial realities, particularly in the case of Cambrian Biologics, where a significant increase in inventory raises concerns about the sustainability of its stock price [1][4]. - Goldman Sachs raised the target price for Cambrian Biologics to 2104 yuan based on three reasons: explosive earnings growth, industry benefits, and domestic substitution, but the article suggests that these reasons may be misleading [1][4]. - The article emphasizes the importance of focusing on data rather than narratives, pointing out that Cambrian Biologics itself acknowledged that its stock price is detached from its fundamentals [4]. Group 2 - The article discusses the phenomenon in the A-share market where news often comes too late, leading to a "buy the rumor, sell the news" mentality, which can result in capital gains before the news is even reported [5]. - It provides examples of companies like Dize Pharmaceutical and Nari Radar, illustrating how market reactions can defy expectations, with institutional investors sometimes acting contrary to public sentiment [6][11]. - The article advocates for the use of quantitative tools to track institutional investment flows, suggesting that these tools can provide clearer insights into market movements than traditional analysis [14].